FoRx Therapeutics
Latest round
- Series A
Last raised
- Dec 2025
Total raised
- $60M
Investors
- 5
About FoRx Therapeutics
Based in Switzerland, and founded in 2019, FoRx Therapeutics AG focuses on developing therapeutic compounds that target key molecular pathways in cancer treatment. As of January 2026, Tarig Bashir is Chief Executive Officer (CEO) of the company. FoRx Therapeutics specializes in the development of first-in-class compounds targeting key molecular pathways involved in DNA replication stress, a novel approach in the field of cancer treatment. The company is focused on creating targeted anticancer drugs that address the critical challenges associated with DNA Damage Response pathways. These compounds are primarily aimed at oncologists and healthcare institutions seeking innovative treatments for various types of cancer, with the potential to enhance patient outcomes through more effective therapeutic options. Currently, FoRx Therapeutics is engaged in the early stages of drug development, and while specific product names and release dates are not disclosed, the company is poised to serve markets in North America and Europe, where there is a significant demand for advanced cancer therapies. FoRx Therapeutics operates on a business model that involves partnerships with pharmaceutical companies and research institutions to advance its drug development initiatives. Given the innovative nature of their offerings, the company is expected to engage in B2B transactions, collaborating with healthcare providers and oncology specialists who will administer these therapies to patients. Specific pricing plans or details regarding transaction structures have not been disclosed, but the focus on developing targeted compounds suggests a framework that supports strategic alliances within the biopharmaceutical industry.
Who invested in FoRx Therapeutics
5 investors across 2 rounds
See all investors in FoRx Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about FoRx Therapeutics
Who invested in FoRx Therapeutics?
FoRx Therapeutics has 5 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has FoRx Therapeutics raised?
FoRx Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did FoRx Therapeutics last raise money?
FoRx Therapeutics's most recent round on record is a Series A, in Dec 2025.
What does FoRx Therapeutics do?
Based in Switzerland, and founded in 2019, FoRx Therapeutics AG focuses on developing therapeutic compounds that target key molecular pathways in cancer treatment.
Where is FoRx Therapeutics headquartered?
FoRx Therapeutics is headquartered in Basel, Switzerland.
Which VCs invest in companies like FoRx Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at FoRx Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like FoRx Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.